
    
      After being informed about the study and potential risks, all patients who meet all
      eligibility criteria and who give written informed consent will be randomized to receive
      standard care or standard care plus lopinavir/ritonavir (400mg/100mg twice daily for 14
      days). Participants will receive daily visits from study staff for 15 days and be followed
      for a total of 28 days.
    
  